

SUPPLEMENTARY TABLES

Supplementary Table 1. Detailed clinical data for all 365 TCGA-LIHC patients.

	High (N = 105)	Low (N = 260)	P value
OS:			0.002
Alive	54 (51.4%)	181 (69.6%)	
Dead	51 (48.6%)	79 (30.4%)	
Gender:			0.576
Female	37 (35.2%)	82 (31.5%)	
Male	68 (64.8%)	178 (68.5%)	
Age:			0.043
≤60	59 (56.2%)	114 (43.8%)	
>60	46 (43.8%)	146 (56.2%)	
Stage:			0.002
Stage I	36 (36.4%)	134 (55.4%)	
Stage II	28 (28.3%)	56 (23.1%)	
Stage III	35 (35.4%)	48 (19.8%)	
Stage IV	0 (0.00%)	4 (1.65%)	
Grade:			0.003
G1	9 (8.57%)	46 (18.0%)	
G2	44 (41.9%)	131 (51.4%)	
G3	46 (43.8%)	72 (28.2%)	
G4	6 (5.71%)	6 (2.35%)	
T. Stage:			0.008
T1	38 (36.2%)	142 (55.0%)	
T2	31 (29.5%)	60 (23.3%)	
T3	32 (30.5%)	46 (17.8%)	
T4	4 (3.81%)	9 (3.49%)	
TX	0 (0.00%)	1 (0.39%)	
N. Stage:			0.688
N0	75 (72.1%)	173 (66.5%)	
N1	1 (0.96%)	3 (1.15%)	
NX	28 (26.9%)	84 (32.3%)	
M. Stage:			0.354
M0	81 (77.1%)	182 (70.0%)	
M1	0 (0.00%)	3 (1.15%)	
MX	24 (22.9%)	75 (28.8%)	
mTOR	1.32 [1.31;1.34]	1.30 [1.29;1.31]	<0.001

Supplementary Table 2. Detailed clinical data for 243 ICGC-LIRI-JP patients.

	High (N = 77)	Low (N = 166)	P value
OS:			0.019
Alive	56 (72.7%)	143 (86.1%)	
Dead	21 (27.3%)	23 (13.9%)	
Gender:			0.957
Female	20 (26.0%)	41 (24.7%)	
Male	57 (74.0%)	125 (75.3%)	
Age:			0.823
≤60	17 (22.1%)	33 (19.9%)	
>60	60 (77.9%)	133 (80.1%)	
Stage:			0.375
Stage I	10 (13.0%)	26 (15.7%)	
Stage II	30 (39.0%)	80 (48.2%)	
Stage III	29 (37.7%)	47 (28.3%)	
Stage IV	8 (10.4%)	13 (7.83%)	
mTOR	0.63 (0.03)	0.60 (0.03)	<0.001